944896-42-8

Basic information

• Product Name: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid
• Synonyms: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid;IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-;6-Bromo-3-carboxyimidazo[1,2-a]pyridine
• CAS NO: 944896-42-8
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.044
• Mol File: 944896-42-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 1.899 g/cm³
• Refractive Index: 1.728
• Storage Temp.: 2-8°C
• PKA: -0.99±0.41(Predicted)
• CAS DataBase Reference: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid(944896-42-8)
• EPA Substance Registry System: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid(944896-42-8)

Safety Data

• Hazardous Substances Data: 944896-42-8(Hazardous Substances Data)

Usage

Description

6-Bromoimidazo[1,2-a]pyridine-3-carboxylic acid is a heterocyclic compound characterized by the presence of nitrogen and sulfur atoms in its structure. It is a derivative of imidazo[1,2-a]pyridine, with a bromine atom at the 6th position and a carboxylic acid group at the 3rd position. This unique molecular structure endows it with potential applications in various fields, particularly as a pharmaceutical intermediate.

Uses

Used in Pharmaceutical Industry:
6-Bromoimidazo[1,2-a]pyridine-3-carboxylic acid is used as a pharmaceutical intermediate for the synthesis of various drugs and drug candidates. Its heterocyclic nature allows for the development of compounds with diverse biological activities, making it a valuable building block in medicinal chemistry.
As a pharmaceutical intermediate, 6-Bromoimidazo[1,2-a]pyridine-3-carboxylic acid can be utilized in the design and synthesis of new drugs targeting a wide range of therapeutic areas. Its unique structure can be further modified through chemical reactions to create derivatives with specific pharmacological properties, enhancing its potential as a versatile compound in drug discovery and development.

InChI:InChI=1/C8H5BrN2O2/c9-5-1-2-7-10-3-6(8(12)13)11(7)4-5/h1-4H,(H,12,13)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 372198-69-1 ethyl 6-bromoimidazol[1,2-a]pyridine-3-carboxylate 
• 33142-21-1 ethyl 2-chloro-3-oxopropanoate 
• 474708-98-0 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile 
• 138888-98-9 N’-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide 
• 1359656-01-1 methyl 6-bromoimidazo[1,2-a]pyridine-3-carboxylate 
• 138240-34-3 (E)-N’-(5-bromopyridin-2-yl)-N,N-dimethylformamidine 

Downstream Products

• 1296201-66-5 6-bromo-N-(3-methoxybenzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426448-31-8 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426448-87-4 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]imidazo[1,2-a]pyridine-3-carboxamide 
• 1426449-72-0 6-bromo-N-(5-(5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1268454-23-4 (6-(2-aminobenzo[d]oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl)(morpholino)methanone 
• 1426671-16-0 6-bromo-N-(2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-97-3 N-(5-(2-tert-butoxyethylcarbamoyl)-2-fluorophenyl)-7-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 2044706-79-6 6-bromoimidazo[1,2-a]pyridine-3-carboxamide 
• 474708-98-0 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile 

Relevant articles and documents

Discovery of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors

Inhibition of cdc2-like kinase1 (CLK1) could efficiently induce autophagy and it has been thought as a potential target for treatment of autophagy-related diseases. Herein we report the discovery of a series of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors. Among them, compound 9e is the most potent one, which exhibits an IC50 value of 4 nM against CLK1 kinase. In vitro, this compound reduces the phosphorylation level of the typical downstream substrates of CLK1 and affects their subcellular redistribution. Further study indicates that 9e is efficient to induce autophagy. Overall, this study provides a promising lead compound for drug discovery targeting CLK1 kinase.

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV

The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.